

Product datasheet for **TL314594V**

SERCA2 (ATP2A2) Human shRNA Lentiviral Particle (Locus ID 488)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	SERCA2 (ATP2A2) Human shRNA Lentiviral Particle (Locus ID 488)
Locus ID:	488
Synonyms:	ATP2B; DAR; DD; DKFZp686P0211; FLJ20293; FLJ38063; MGC45367; SERCA2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ATP2A2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001135765 , NM_001681 , NM_170665 , NM_170665.1 , NM_170665.2 , NM_170665.3 , NM_001681.2 , NM_001681.3 , NM_001135765.1 , BC035588 , BC035588.1 , BC065753 , NM_001681.4 , NM_170665.4
UniProt ID:	P16615
Summary:	This gene encodes one of the SERCA Ca ²⁺ -ATPases, which are intracellular pumps located in the sarcoplasmic or endoplasmic reticula of the skeletal muscle. This enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol into the sarcoplasmic reticulum lumen, and is involved in regulation of the contraction/relaxation cycle. Mutations in this gene cause Darier-White disease, also known as keratosis follicularis, an autosomal dominant skin disorder characterized by loss of adhesion between epidermal cells and abnormal keratinization. Other types of mutations in this gene have been associated with various forms of muscular dystrophies. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2019]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).